Literature DB >> 22740584

Resampling-based methods in single and multiple testing for equality of covariance/correlation matrices.

Yang Yang1, Victor DeGruttola.   

Abstract

Traditional resampling-based tests for homogeneity in covariance matrices across multiple groups resample residuals, that is, data centered by group means. These residuals do not share the same second moments when the null hypothesis is false, which makes them difficult to use in the setting of multiple testing. An alternative approach is to resample standardized residuals, data centered by group sample means and standardized by group sample covariance matrices. This approach, however, has been observed to inflate type I error when sample size is small or data are generated from heavy-tailed distributions. We propose to improve this approach by using robust estimation for the first and second moments. We discuss two statistics: the Bartlett statistic and a statistic based on eigen-decomposition of sample covariance matrices. Both statistics can be expressed in terms of standardized errors under the null hypothesis. These methods are extended to test homogeneity in correlation matrices. Using simulation studies, we demonstrate that the robust resampling approach provides comparable or superior performance, relative to traditional approaches, for single testing and reasonable performance for multiple testing. The proposed methods are applied to data collected in an HIV vaccine trial to investigate possible determinants, including vaccine status, vaccine-induced immune response level and viral genotype, of unusual correlation pattern between HIV viral load and CD4 count in newly infected patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740584      PMCID: PMC5027617          DOI: 10.1515/1557-4679.1388

Source DB:  PubMed          Journal:  Int J Biostat        ISSN: 1557-4679            Impact factor:   0.968


  7 in total

1.  A general distribution theory for a class of likelihood criteria.

Authors:  G E P BOX
Journal:  Biometrika       Date:  1949-12       Impact factor: 2.445

2.  Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data.

Authors:  Peter B Gilbert; Yuying Jin
Journal:  Biostatistics       Date:  2009-10-08       Impact factor: 5.899

3.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Authors:  Peter B Gilbert; Michael L Peterson; Dean Follmann; Michael G Hudgens; Donald P Francis; Marc Gurwith; William L Heyward; David V Jobes; Vladimir Popovic; Steven G Self; Faruk Sinangil; Donald Burke; Phillip W Berman
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

4.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

5.  Killing of primary CD4+ T cells by non-syncytium-inducing macrophage-tropic human immunodeficiency virus type 1.

Authors:  X Yu; M F McLane; L Ratner; W O'Brien; R Collman; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

6.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

7.  Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120.

Authors:  C Süsal; M Kirschfink; M Kröpelin; V Daniel; G Opelz
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.